1
|
Leoni A, Locatelli A, Morigi R, Rambaldi M. Novel thiazole derivatives: a patent review (2008 – 2012. Part 2). Expert Opin Ther Pat 2014; 24:759-77. [DOI: 10.1517/13543776.2014.910196] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/14/2023]
|
2
|
Riether D. Selective cannabinoid receptor 2 modulators: a patent review 2009--present. Expert Opin Ther Pat 2012; 22:495-510. [PMID: 22537079 DOI: 10.1517/13543776.2012.682570] [Citation(s) in RCA: 24] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Abstract
INTRODUCTION The activation of the cannabinoid receptor 2 (CB2) affects a myriad of immune responses from inflammation to neuroprotection, demonstrates analgesic effects and suppresses responses in many animal models of pain. Questions around the involvement of CB1 activation in these effects remain, but efforts have been directed toward the discovery of highly selective CB2 modulators lacking the psychotropic effects of cannabinoids, which are mediated by the CB1 receptor. AREAS COVERED This review covers the patent literature which was published since April 2009 on CB2 selective modulators. It provides a general summary of the CB2 biology supporting the interest in CB2 as a drug target, new potential therapeutic indications and the development status of selective CB2 agonists. EXPERT OPINION There is a continuous interest in the CB2 receptor as a drug target. Many highly selective compounds of various chemotypes have been identified and their analgesic effects in animal models further support the potential of this mechanism in pain therapy. Several companies have initiated clinical trials. While some of these have been terminated for various reasons, one can anticipate the emergence of new drugs from CB2 modulation once a better understanding around the cannabinoid receptors is gained.
Collapse
Affiliation(s)
- Doris Riether
- Boehringer Ingelheim Pharma GmbH & Co. KG, Birkendorfer Strasse 65, D-88397 Biberach an der Riss, Germany.
| |
Collapse
|
3
|
|
4
|
An expedient atom-efficient synthesis of the cannabinoid CB1 receptor inverse agonist ibipinabant. Tetrahedron Lett 2011. [DOI: 10.1016/j.tetlet.2011.01.068] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/23/2022]
|
5
|
Pasquini S, Ligresti A, Mugnaini C, Semeraro T, Cicione L, De Rosa M, Guida F, Luongo L, De Chiaro M, Cascio MG, Bolognini D, Marini P, Pertwee R, Maione S, Marzo VD, Corelli F. Investigations on the 4-Quinolone-3-carboxylic Acid Motif. 3. Synthesis, Structure−Affinity Relationships, and Pharmacological Characterization of 6-Substituted 4-Quinolone-3-carboxamides as Highly Selective Cannabinoid-2 Receptor Ligands. J Med Chem 2010; 53:5915-28. [DOI: 10.1021/jm100123x] [Citation(s) in RCA: 32] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/08/2023]
Affiliation(s)
- Serena Pasquini
- Dipartimento Farmaco Chimico Tecnologico, Università degli Studi di Siena, Via A. Moro, 53100 Siena, Italy
| | - Alessia Ligresti
- Endocannabinoid Research Group, Institute of Biomolecular Chemistry, Consiglio Nazionale delle Ricerche, Via dei Campi Flegrei 34, 80078 Pozzuoli (Naples), Italy
| | - Claudia Mugnaini
- Dipartimento Farmaco Chimico Tecnologico, Università degli Studi di Siena, Via A. Moro, 53100 Siena, Italy
| | - Teresa Semeraro
- Dipartimento Farmaco Chimico Tecnologico, Università degli Studi di Siena, Via A. Moro, 53100 Siena, Italy
| | - Lavinia Cicione
- Dipartimento Farmaco Chimico Tecnologico, Università degli Studi di Siena, Via A. Moro, 53100 Siena, Italy
| | - Maria De Rosa
- Dipartimento Farmaco Chimico Tecnologico, Università degli Studi di Siena, Via A. Moro, 53100 Siena, Italy
| | - Francesca Guida
- Department of Experimental Medicine—Section of Pharmacology “L. Donatelli”, Second University of Naples, Via S. Maria di Costantinopoli 16, 80138 Naples, Italy
| | - Livio Luongo
- Department of Experimental Medicine—Section of Pharmacology “L. Donatelli”, Second University of Naples, Via S. Maria di Costantinopoli 16, 80138 Naples, Italy
| | - Maria De Chiaro
- Department of Experimental Medicine—Section of Pharmacology “L. Donatelli”, Second University of Naples, Via S. Maria di Costantinopoli 16, 80138 Naples, Italy
| | - Maria Grazia Cascio
- Institute of Medical Sciences University of Aberdeen, Aberdeen AB25 2ZD, Scotland, U.K
| | - Daniele Bolognini
- DBSF, Pharmacology Section and Neuroscience Centre, University of Insubria, Busto Arsizio (Va), Italy
- Institute of Medical Sciences University of Aberdeen, Aberdeen AB25 2ZD, Scotland, U.K
| | - Pietro Marini
- Institute of Medical Sciences University of Aberdeen, Aberdeen AB25 2ZD, Scotland, U.K
| | - Roger Pertwee
- Institute of Medical Sciences University of Aberdeen, Aberdeen AB25 2ZD, Scotland, U.K
| | - Sabatino Maione
- Department of Experimental Medicine—Section of Pharmacology “L. Donatelli”, Second University of Naples, Via S. Maria di Costantinopoli 16, 80138 Naples, Italy
| | - Vincenzo Di Marzo
- Endocannabinoid Research Group, Institute of Biomolecular Chemistry, Consiglio Nazionale delle Ricerche, Via dei Campi Flegrei 34, 80078 Pozzuoli (Naples), Italy
| | - Federico Corelli
- Dipartimento Farmaco Chimico Tecnologico, Università degli Studi di Siena, Via A. Moro, 53100 Siena, Italy
| |
Collapse
|
6
|
Lange JH, van der Neut MA, den Hartog AP, Wals HC, Hoogendoorn J, van Stuivenberg HH, van Vliet BJ, Kruse CG. Synthesis, SAR and intramolecular hydrogen bonding pattern of 1,3,5-trisubstituted 4,5-dihydropyrazoles as potent cannabinoid CB1 receptor antagonists. Bioorg Med Chem Lett 2010; 20:1752-7. [DOI: 10.1016/j.bmcl.2010.01.049] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/17/2009] [Revised: 01/05/2010] [Accepted: 01/06/2010] [Indexed: 10/19/2022]
|
7
|
Lange JH, van der Neut MA, Wals HC, Kuil GD, Borst AJ, Mulder A, den Hartog AP, Zilaout H, Goutier W, van Stuivenberg HH, van Vliet BJ. Synthesis and SAR of novel imidazoles as potent and selective cannabinoid CB2 receptor antagonists with high binding efficiencies. Bioorg Med Chem Lett 2010; 20:1084-9. [DOI: 10.1016/j.bmcl.2009.12.032] [Citation(s) in RCA: 21] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/10/2009] [Revised: 12/04/2009] [Accepted: 12/06/2009] [Indexed: 10/20/2022]
|
8
|
Gilbert EJ, Zhou G, Wong MK, Tong L, Shankar BB, Huang C, Kelly J, Lavey BJ, McCombie SW, Chen L, Rizvi R, Dong Y, Shu Y, Kozlowski JA, Shih NY, Hipkin RW, Gonsiorek W, Malikzay A, Lunn CA, Favreau L, Lundell DJ. Non-aromatic A-ring replacement in the triaryl bis-sulfone CB2 receptor inhibitors. Bioorg Med Chem Lett 2010; 20:608-11. [DOI: 10.1016/j.bmcl.2009.11.084] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/06/2009] [Revised: 11/16/2009] [Accepted: 11/17/2009] [Indexed: 11/29/2022]
|
9
|
|
10
|
Synthesis and SAR of 1,4,5,6-tetrahydropyridazines as potent cannabinoid CB1 receptor antagonists. Bioorg Med Chem Lett 2009; 19:5675-8. [DOI: 10.1016/j.bmcl.2009.08.007] [Citation(s) in RCA: 23] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/17/2009] [Revised: 08/03/2009] [Accepted: 08/04/2009] [Indexed: 11/24/2022]
|
11
|
Worm K, Weaver DG, Green RC, Saeui CT, Dulay DMS, Barker WM, Cassel JA, Stabley GJ, DeHaven RN, LaBuda CJ, Koblish M, Brogdon BL, Smith SA, Dolle RE. Discovery of N-(3-(morpholinomethyl)-phenyl)-amides as potent and selective CB2 agonists. Bioorg Med Chem Lett 2009; 19:5004-8. [DOI: 10.1016/j.bmcl.2009.07.057] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/15/2009] [Revised: 07/08/2009] [Accepted: 07/09/2009] [Indexed: 01/27/2023]
|
12
|
Hou DR, Alam S, Kuan TC, Ramanathan M, Lin TP, Hung MS. 1,2,3-Triazole derivatives as new cannabinoid CB1 receptor antagonists. Bioorg Med Chem Lett 2009; 19:1022-5. [DOI: 10.1016/j.bmcl.2008.11.029] [Citation(s) in RCA: 41] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/24/2008] [Revised: 11/05/2008] [Accepted: 11/11/2008] [Indexed: 11/16/2022]
|
13
|
Chapter 11 Recent Advances in the Discovery of CB2 Selective Agonists. ANNUAL REPORTS IN MEDICINAL CHEMISTRY 2009. [DOI: 10.1016/s0065-7743(09)04411-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register]
|
14
|
Childers WE, Gilbert AM, Kennedy JD, Whiteside GT. Advances in the development of novel analgesics. Expert Opin Ther Pat 2008. [DOI: 10.1517/13543776.18.9.1027] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022]
|
15
|
Tseng SL, Hung MS, Chang CP, Song JS, Tai CL, Chiu HH, Hsieh WP, Lin Y, Chung WL, Kuo CW, Wu CH, Chu CM, Tung YS, Chao YS, Shia KS. Bioisosteric Replacement of the Pyrazole 5-Aryl Moiety of N-(Piperidin-1-yl)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide (SR141716A). A Novel Series of Alkynylthiophenes as Potent and Selective Cannabinoid-1 Receptor Antagonists. J Med Chem 2008; 51:5397-412. [DOI: 10.1021/jm800066v] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Affiliation(s)
- Shi-Liang Tseng
- Division of Biotechnology and Pharmaceutical Research, National Health Research Institutes, No. 35, Keyan Road, Zhunan Town, Miaoli County 350, Taiwan, ROC
| | - Ming-Shiu Hung
- Division of Biotechnology and Pharmaceutical Research, National Health Research Institutes, No. 35, Keyan Road, Zhunan Town, Miaoli County 350, Taiwan, ROC
| | - Chun-Ping Chang
- Division of Biotechnology and Pharmaceutical Research, National Health Research Institutes, No. 35, Keyan Road, Zhunan Town, Miaoli County 350, Taiwan, ROC
| | - Jen-Shin Song
- Division of Biotechnology and Pharmaceutical Research, National Health Research Institutes, No. 35, Keyan Road, Zhunan Town, Miaoli County 350, Taiwan, ROC
| | - Chia-Liang Tai
- Division of Biotechnology and Pharmaceutical Research, National Health Research Institutes, No. 35, Keyan Road, Zhunan Town, Miaoli County 350, Taiwan, ROC
| | - Hua-Hao Chiu
- Division of Biotechnology and Pharmaceutical Research, National Health Research Institutes, No. 35, Keyan Road, Zhunan Town, Miaoli County 350, Taiwan, ROC
| | - Wan-Ping Hsieh
- Division of Biotechnology and Pharmaceutical Research, National Health Research Institutes, No. 35, Keyan Road, Zhunan Town, Miaoli County 350, Taiwan, ROC
| | - Yinchiu Lin
- Division of Biotechnology and Pharmaceutical Research, National Health Research Institutes, No. 35, Keyan Road, Zhunan Town, Miaoli County 350, Taiwan, ROC
| | - Wan-Ling Chung
- Division of Biotechnology and Pharmaceutical Research, National Health Research Institutes, No. 35, Keyan Road, Zhunan Town, Miaoli County 350, Taiwan, ROC
| | - Chun-Wei Kuo
- Division of Biotechnology and Pharmaceutical Research, National Health Research Institutes, No. 35, Keyan Road, Zhunan Town, Miaoli County 350, Taiwan, ROC
| | - Chien-Huang Wu
- Division of Biotechnology and Pharmaceutical Research, National Health Research Institutes, No. 35, Keyan Road, Zhunan Town, Miaoli County 350, Taiwan, ROC
| | - Cheng-Ming Chu
- Division of Biotechnology and Pharmaceutical Research, National Health Research Institutes, No. 35, Keyan Road, Zhunan Town, Miaoli County 350, Taiwan, ROC
| | - Yen-Shih Tung
- Division of Biotechnology and Pharmaceutical Research, National Health Research Institutes, No. 35, Keyan Road, Zhunan Town, Miaoli County 350, Taiwan, ROC
| | - Yu-Sheng Chao
- Division of Biotechnology and Pharmaceutical Research, National Health Research Institutes, No. 35, Keyan Road, Zhunan Town, Miaoli County 350, Taiwan, ROC
| | - Kak-Shan Shia
- Division of Biotechnology and Pharmaceutical Research, National Health Research Institutes, No. 35, Keyan Road, Zhunan Town, Miaoli County 350, Taiwan, ROC
| |
Collapse
|
16
|
DiMauro EF, Buchanan JL, Cheng A, Emkey R, Hitchcock SA, Huang L, Huang MY, Janosky B, Lee JH, Li X, Martin MW, Tomlinson SA, White RD, Zheng XM, Patel VF, Fremeau RT. Structural modifications of N-arylamide oxadiazoles: Identification of N-arylpiperidine oxadiazoles as potent and selective agonists of CB2. Bioorg Med Chem Lett 2008; 18:4267-74. [DOI: 10.1016/j.bmcl.2008.06.096] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/27/2008] [Revised: 06/26/2008] [Accepted: 06/30/2008] [Indexed: 10/21/2022]
|
17
|
Chu CM, Hung MS, Hsieh MT, Kuo CW, T. D. S, Song JS, Chiu HH, Chao YS, Shia KS. Bioisosteric replacement of the pyrazole 3-carboxamide moiety of rimonabant. A novel series of oxadiazoles as CB1 cannabinoid receptor antagonists. Org Biomol Chem 2008; 6:3399-407. [DOI: 10.1039/b807648k] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/22/2022]
|